Who is sponsoring NCT01732627?

NCT01732627 is sponsored by Sanofi Pasteur, a Sanofi Company.

What drugs are being tested in NCT01732627?

Interventions in NCT01732627: Meningococcal Polysaccharide (A, C, Y, and W 135) Tetanus Protein Conjugate Vaccine, Meningococcal Polysaccharide Vaccine, Groups A, C, Y, W 135 Combined.

What condition does NCT01732627 study?

NCT01732627 studies Meningitis, Meningococcal Meningitis, Meningococcal Infections, Invasive Meningococcal Disease.

Is NCT01732627 still recruiting?

NCT01732627 is currently completed. Last updated 4 April 2022.

Are results published for NCT01732627?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2022-04-04 · How we verify

NCT01732627

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of a Quadrivalent Meningococcal Conjugate Vaccine in Subjects Aged 56 and Older

Completed Phase 2 Results posted Last updated 4 April 2022

What this trial tests

Phase 2 trial testing Meningococcal Polysaccharide (A, C, Y, and W 135) Tetanus Protein Conjugate Vaccine in Meningitis in 301 participants. Completed in 17 January 2013.

Timeline

12 November 2012

Primary endpoint
17 January 2013

17 January 2013

Quick facts

Lead sponsor	Sanofi Pasteur, a Sanofi Company
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	301
Start date	12 November 2012
Primary completion	17 January 2013
Estimated completion	17 January 2013
Sites	12 locations across United States

Drugs / interventions tested

Meningococcal Polysaccharide (A, C, Y, and W 135) Tetanus Protein Conjugate Vaccine — full drug profile →
Meningococcal Polysaccharide Vaccine, Groups A, C, Y, W 135 Combined — full drug profile →

Conditions studied

Meningitis — all drugs for Meningitis →
Meningococcal Meningitis — all drugs for Meningococcal Meningitis →
Meningococcal Infections — all drugs for Meningococcal Infections →
Invasive Meningococcal Disease — all drugs for Invasive Meningococcal Disease →

Sponsor

Sanofi Pasteur, a Sanofi Company — full company profile →

Who can join

56 and older, any sex, with Meningitis or Meningococcal Meningitis. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Percentage of Participants With Antibody Titers ≥1:4 and ≥1:8 Measured by Serum Bactericidal Assay Using Human Complement (hSBA) Against Meningococcal Serogroups A, C, Y, and W 135 Before Vaccination With MenACYW Conjugate Vaccine or Menomune® Vaccine Primary · Day 0 (pre-vaccination)

Antibody titers against meningococcal serogroups A, C, Y, and W 135 were measured by hSBA assay method.

Serogroup A: ≥1:4

Group	Value	95% CI
Group 1: MenACYW Conjugate Vaccine	95.9	92.1 – 98.2
Group 2: Menomune® A/C/Y/W 135 Vaccine	96.8	91.0 – 99.3

Serogroup A: ≥1:8

Group	Value	95% CI
Group 1: MenACYW Conjugate Vaccine	76.4	69.8 – 82.2
Group 2: Menomune® A/C/Y/W 135 Vaccine	79.8	70.2 – 87.4

Serogroup C: ≥1:4

Group	Value	95% CI
Group 1: MenACYW Conjugate Vaccine	27.7	21.5 – 34.5
Group 2: Menomune® A/C/Y/W 135 Vaccine	30.9	21.7 – 41.2

Serogroup C: ≥1:8

Group	Value	95% CI
Group 1: MenACYW Conjugate Vaccine	17.4	12.4 – 23.5
Group 2: Menomune® A/C/Y/W 135 Vaccine	10.6	5.2 – 18.7

Serogroup Y: ≥1:4

Group	Value	95% CI
Group 1: MenACYW Conjugate Vaccine	22.1	16.4 – 28.5
Group 2: Menomune® A/C/Y/W 135 Vaccine	26.6	18.0 – 36.7

Serogroup Y: ≥1:8

Group	Value	95% CI
Group 1: MenACYW Conjugate Vaccine	13.3	8.9 – 18.9
Group 2: Menomune® A/C/Y/W 135 Vaccine	24.5	16.2 – 34.4

Serogroup W 135: ≥1:4

Group	Value	95% CI
Group 1: MenACYW Conjugate Vaccine	26.2	20.1 – 32.9
Group 2: Menomune® A/C/Y/W 135 Vaccine	26.6	18.0 – 36.7

Serogroup W 135: ≥1:8

Group	Value	95% CI
Group 1: MenACYW Conjugate Vaccine	13.3	8.9 – 18.9
Group 2: Menomune® A/C/Y/W 135 Vaccine	8.5	3.7 – 16.1

Percentage of Participants With Antibody Titers ≥1:4 and ≥1:8 Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W 135 Following Vaccination With MenACYW Conjugate Vaccine or Menomune® Vaccine Primary · Day 30 (post-vaccination)

Antibody titers against meningococcal serogroups A, C, Y, and W 135 were measured by hSBA assay method.

Serogroup A: ≥1:4

Group	Value	95% CI
Group 1: MenACYW Conjugate Vaccine	97.4	94.1 – 99.2
Group 2: Menomune® A/C/Y/W 135 Vaccine	93.6	86.6 – 97.6

Serogroup A: ≥1:8

Group	Value	95% CI
Group 1: MenACYW Conjugate Vaccine	93.8	89.5 – 96.8
Group 2: Menomune® A/C/Y/W 135 Vaccine	85.1	76.3 – 91.6

Serogroup C: ≥1:4

Group	Value	95% CI
Group 1: MenACYW Conjugate Vaccine	85.6	79.9 – 90.2
Group 2: Menomune® A/C/Y/W 135 Vaccine	79.8	70.2 – 87.4

Serogroup C: ≥1:8

Group	Value	95% CI
Group 1: MenACYW Conjugate Vaccine	74.9	68.2 – 80.8
Group 2: Menomune® A/C/Y/W 135 Vaccine	62.8	52.2 – 72.5

Serogroup Y: ≥1:4

Group	Value	95% CI
Group 1: MenACYW Conjugate Vaccine	87.2	81.7 – 91.5
Group 2: Menomune® A/C/Y/W 135 Vaccine	73.4	63.3 – 82.0

Serogroup Y: ≥1:8

Group	Value	95% CI
Group 1: MenACYW Conjugate Vaccine	80.5	74.2 – 85.8
Group 2: Menomune® A/C/Y/W 135 Vaccine	59.6	49.0 – 69.6

Serogroup W 135: ≥1:4

Group	Value	95% CI
Group 1: MenACYW Conjugate Vaccine	88.7	83.4 – 92.8
Group 2: Menomune® A/C/Y/W 135 Vaccine	77.7	67.9 – 85.6

Serogroup W 135: ≥1:8

Group	Value	95% CI
Group 1: MenACYW Conjugate Vaccine	79.5	73.1 – 84.9
Group 2: Menomune® A/C/Y/W 135 Vaccine	60.6	50.0 – 70.6

Percentage of Participants With Vaccine Seroresponse Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W 135 Following Vaccination With MenACYW Conjugate Vaccine or Menomune® Vaccine Primary · Day 30 (post-vaccination)

Vaccine seroresponse for serogroups A, C, Y, and W 135 was measured by hSBA assay method. Seroresponse was defined as post-vaccination hSBA titers ≥1:8 for participants with pre-vaccination hSBA titers less than (\<) 1:8, or at least a 4-fold increase in hSBA titers from pre- to post-vaccination for participants with pre-vaccination hSBA titers ≥1:8.

Serogroup A

Group	Value	95% CI
Group 1: MenACYW Conjugate Vaccine	65.1	58.0 – 71.8
Group 2: Menomune® A/C/Y/W 135 Vaccine	46.8	36.4 – 57.4

Serogroup C

Group	Value	95% CI
Group 1: MenACYW Conjugate Vaccine	70.8	63.8 – 77.0
Group 2: Menomune® A/C/Y/W 135 Vaccine	59.6	49.0 – 69.6

Serogroup Y

Group	Value	95% CI
Group 1: MenACYW Conjugate Vaccine	75.4	68.7 – 81.3
Group 2: Menomune® A/C/Y/W 135 Vaccine	48.9	38.5 – 59.5

Serogroup W 135

Group	Value	95% CI
Group 1: MenACYW Conjugate Vaccine	74.4	67.6 – 80.3
Group 2: Menomune® A/C/Y/W 135 Vaccine	55.3	44.7 – 65.6

Geometric Mean Titers (GMTs) of Antibodies Against Meningococcal Serogroups A, C, Y, and W 135 Measured by hSBA Before Vaccination With MenACYW Conjugate Vaccine or Menomune® Vaccine Primary · Day 0 (pre-vaccination)

GMTs of antibodies against meningococcal serogroups A, C, Y, and W 135 were measured by hSBA assay method.

Serogroup A

Group	Value	95% CI
Group 1: MenACYW Conjugate Vaccine	9.73	8.65 – 10.9
Group 2: Menomune® A/C/Y/W 135 Vaccine	10.4	8.58 – 12.5

Serogroup C

Group	Value	95% CI
Group 1: MenACYW Conjugate Vaccine	3.32	2.87 – 3.85
Group 2: Menomune® A/C/Y/W 135 Vaccine	2.87	2.49 – 3.31

Serogroup Y

Group	Value	95% CI
Group 1: MenACYW Conjugate Vaccine	3.02	2.63 – 3.47
Group 2: Menomune® A/C/Y/W 135 Vaccine	3.53	2.84 – 4.38

Serogroup W 135

Group	Value	95% CI
Group 1: MenACYW Conjugate Vaccine	2.83	2.56 – 3.14
Group 2: Menomune® A/C/Y/W 135 Vaccine	2.83	2.40 – 3.33

Geometric Mean Titers (GMTs) of Antibodies Against Meningococcal Serogroups A, C, Y, and W 135 Measured by hSBA Following Vaccination With MenACYW Conjugate Vaccine or Menomune® Vaccine Primary · Day 30 (post-vaccination)

GMTs of antibodies against meningococcal serogroups A, C, Y, and W 135 were measured by hSBA assay method.

Serogroup A

Group	Value	95% CI
Group 1: MenACYW Conjugate Vaccine	51.0	40.7 – 63.9
Group 2: Menomune® A/C/Y/W 135 Vaccine	31.8	22.5 – 44.9

Serogroup C

Group	Value	95% CI
Group 1: MenACYW Conjugate Vaccine	48.3	34.8 – 67.1
Group 2: Menomune® A/C/Y/W 135 Vaccine	18.5	12.1 – 28.3

Serogroup Y

Group	Value	95% CI
Group 1: MenACYW Conjugate Vaccine	41.9	31.8 – 55.3
Group 2: Menomune® A/C/Y/W 135 Vaccine	16.6	11.3 – 24.5

Serogroup W 135

Group	Value	95% CI
Group 1: MenACYW Conjugate Vaccine	29.0	22.5 – 37.3
Group 2: Menomune® A/C/Y/W 135 Vaccine	17.1	11.6 – 25.2

Percentage of Participants With Antibody Titers ≥1:8 and ≥1:128 Measured by Serum Bactericidal Assay Using Baby Rabbit Complement (rSBA) Against Meningococcal Serogroups A, C, Y, and W 135 Before Vaccination With MenACYW Conjugate Vaccine or Menomune® Primary · Day 0 (pre-vaccination)

Antibody titers against meningococcal serogroups A, C, Y, and W 135 were measured by rSBA assay method.

Serogroup A: ≥1:8

Group	Value	95% CI
Group 1: MenACYW Conjugate Vaccine	28.2	22.0 – 35.1
Group 2: Menomune® A/C/Y/W 135 Vaccine	26.9	18.2 – 37.1

Serogroup A: ≥1:128

Group	Value	95% CI
Group 1: MenACYW Conjugate Vaccine	22.1	16.4 – 28.5
Group 2: Menomune® A/C/Y/W 135 Vaccine	22.6	14.6 – 32.4

Serogroup C: ≥1:8

Group	Value	95% CI
Group 1: MenACYW Conjugate Vaccine	12.3	8.0 – 17.8
Group 2: Menomune® A/C/Y/W 135 Vaccine	9.6	4.5 – 17.4

Serogroup C: ≥1:128

Group	Value	95% CI
Group 1: MenACYW Conjugate Vaccine	8.2	4.8 – 13.0
Group 2: Menomune® A/C/Y/W 135 Vaccine	4.3	1.2 – 10.5

Serogroup Y: ≥1:8

Group	Value	95% CI
Group 1: MenACYW Conjugate Vaccine	50.3	43.0 – 57.5
Group 2: Menomune® A/C/Y/W 135 Vaccine	50.0	39.5 – 60.5

Serogroup Y: ≥1:128

Group	Value	95% CI
Group 1: MenACYW Conjugate Vaccine	27.7	21.5 – 34.5
Group 2: Menomune® A/C/Y/W 135 Vaccine	20.2	12.6 – 29.8

Serogroup W 135: ≥1:8

Group	Value	95% CI
Group 1: MenACYW Conjugate Vaccine	20.0	14.6 – 26.3
Group 2: Menomune® A/C/Y/W 135 Vaccine	27.7	18.9 – 37.8

Serogroup W 135: ≥1:128

Group	Value	95% CI
Group 1: MenACYW Conjugate Vaccine	12.8	8.5 – 18.3
Group 2: Menomune® A/C/Y/W 135 Vaccine	14.9	8.4 – 23.7

Percentage of Participants With Antibody Titers ≥1:8 and ≥1:128 Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W 135 Following Vaccination With MenACYW Conjugate Vaccine or Menomune® Primary · Day 30 (post-vaccination)

Antibody titers against meningococcal serogroups A, C, Y, and W 135 were measured by rSBA assay method.

Serogroup A: ≥1:8

Group	Value	95% CI
Group 1: MenACYW Conjugate Vaccine	95.9	92.0 – 98.2
Group 2: Menomune® A/C/Y/W 135 Vaccine	94.7	88.0 – 98.3

Serogroup A: ≥1:128

Group	Value	95% CI
Group 1: MenACYW Conjugate Vaccine	94.3	90.0 – 97.1
Group 2: Menomune® A/C/Y/W 135 Vaccine	89.4	81.3 – 94.8

Serogroup C: ≥1:8

Group	Value	95% CI
Group 1: MenACYW Conjugate Vaccine	95.9	92.0 – 98.2
Group 2: Menomune® A/C/Y/W 135 Vaccine	87.2	78.8 – 93.2

Serogroup C: ≥1:128

Group	Value	95% CI
Group 1: MenACYW Conjugate Vaccine	93.3	88.8 – 96.4
Group 2: Menomune® A/C/Y/W 135 Vaccine	77.7	67.9 – 85.6

Serogroup Y: ≥1:8

Group	Value	95% CI
Group 1: MenACYW Conjugate Vaccine	97.4	94.1 – 99.2
Group 2: Menomune® A/C/Y/W 135 Vaccine	94.7	88.0 – 98.3

Serogroup Y: ≥1:128

Group	Value	95% CI
Group 1: MenACYW Conjugate Vaccine	88.1	82.7 – 92.3
Group 2: Menomune® A/C/Y/W 135 Vaccine	73.4	63.3 – 82.0

Serogroup W 135: ≥1:8

Group	Value	95% CI
Group 1: MenACYW Conjugate Vaccine	98.4	95.5 – 99.7
Group 2: Menomune® A/C/Y/W 135 Vaccine	94.7	88.0 – 98.3

Serogroup W 135: ≥1:128

Group	Value	95% CI
Group 1: MenACYW Conjugate Vaccine	94.3	90.0 – 97.1
Group 2: Menomune® A/C/Y/W 135 Vaccine	79.8	70.2 – 87.4

Percentage of Participants With Vaccine Seroresponse Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W 135 Following Vaccination With MenACYW Conjugate Vaccine or Menomune® Vaccine Primary · Day 30 (post-vaccination)

Vaccine seroresponse for serogroups A, C, Y, and W 135 was measured by rSBA assay method. Seroresponse was defined as post-vaccination rSBA titers ≥1:8 for participants with pre-vaccination rSBA titers \<1:8, or at least a 4-fold increase in rSBA titers from pre- to post-vaccination for participants with pre-vaccination rSBA titers ≥1:8.

Serogroup A

Group	Value	95% CI
Group 1: MenACYW Conjugate Vaccine	90.2	85.1 – 94.0
Group 2: Menomune® A/C/Y/W 135 Vaccine	89.2	81.1 – 94.7

Serogroup C

Group	Value	95% CI
Group 1: MenACYW Conjugate Vaccine	94.8	90.7 – 97.5
Group 2: Menomune® A/C/Y/W 135 Vaccine	86.2	77.5 – 92.4

Serogroup Y

Group	Value	95% CI
Group 1: MenACYW Conjugate Vaccine	86.5	80.9 – 91.0
Group 2: Menomune® A/C/Y/W 135 Vaccine	75.5	65.6 – 83.8

Serogroup W 135

Group	Value	95% CI
Group 1: MenACYW Conjugate Vaccine	95.3	91.3 – 97.8
Group 2: Menomune® A/C/Y/W 135 Vaccine	90.4	82.6 – 95.5

Geometric Mean Titers of Antibodies Against Meningococcal Serogroups A, C, Y, and W 135 Measured by rSBA Before Vaccination With MenACYW Conjugate Vaccine or Menomune® Vaccine Primary · Day 0 (pre-vaccination)

GMTs of antibodies against meningococcal serogroups A, C, Y, and W 135 antibody titers were measured by rSBA assay method.

Serogroup A

Group	Value	95% CI
Group 1: MenACYW Conjugate Vaccine	7.75	5.65 – 10.6
Group 2: Menomune® A/C/Y/W 135 Vaccine	7.32	4.62 – 11.6

Serogroup C

Group	Value	95% CI
Group 1: MenACYW Conjugate Vaccine	3.40	2.76 – 4.18
Group 2: Menomune® A/C/Y/W 135 Vaccine	2.93	2.28 – 3.77

Serogroup Y

Group	Value	95% CI
Group 1: MenACYW Conjugate Vaccine	15.3	11.4 – 20.7
Group 2: Menomune® A/C/Y/W 135 Vaccine	13.1	8.63 – 19.9

Serogroup W 135

Group	Value	95% CI
Group 1: MenACYW Conjugate Vaccine	4.74	3.68 – 6.12
Group 2: Menomune® A/C/Y/W 135 Vaccine	6.05	4.11 – 8.89

Geometric Mean Titers of Antibodies Against Meningococcal Serogroups A, C, Y, and W 135 Measured by rSBA Following Vaccination With MenACYW Conjugate Vaccine or Menomune® Vaccine Primary · Day 30 (post-vaccination)

GMTs of antibodies against meningococcal serogroups A, C, Y, and W 135 antibody titers were measured by rSBA assay method.

Serogroup A

Group	Value	95% CI
Group 1: MenACYW Conjugate Vaccine	1054	825 – 1346
Group 2: Menomune® A/C/Y/W 135 Vaccine	746	501 – 1109

Serogroup C

Group	Value	95% CI
Group 1: MenACYW Conjugate Vaccine	1559	1140 – 2131
Group 2: Menomune® A/C/Y/W 135 Vaccine	445	255 – 776

Serogroup Y

Group	Value	95% CI
Group 1: MenACYW Conjugate Vaccine	591	464 – 753
Group 2: Menomune® A/C/Y/W 135 Vaccine	260	177 – 382

Serogroup W 135

Group	Value	95% CI
Group 1: MenACYW Conjugate Vaccine	910	728 – 1136
Group 2: Menomune® A/C/Y/W 135 Vaccine	493	316 – 772

Number of Participants With Immediate Unsolicited Adverse Events (AEs) After Vaccination Primary · Within 30 minutes after vaccination

An unsolicited AE was an observed AE that did not fulfill the conditions prelisted in the case report form (CRF) in terms of symptom and/or onset post-vaccination. Unsolicited AEs includes both serious and non-serious unsolicited AEs. A serious adverse event (SAE) was any untoward medical occurrence that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event. All participants were obse

Group	Value	95% CI
Group 1: MenACYW Conjugate Vaccine	0
Group 2: Menomune® A/C/Y/W 135 Vaccine	0

Number of Participants With Solicited Injection Site Reactions and Systemic Reactions After Vaccination Primary · Within 7 days after vaccination

A solicited reaction (SR) was an adverse reaction (AR) observed and reported under the conditions (symptom and onset) prelisted in the CRF. Solicited injection site reactions included: pain, erythema, and swelling. Solicited systemic reactions included: fever, headache, malaise and, myalgia.

Pain

Group	Value	95% CI
Group 1: MenACYW Conjugate Vaccine	61
Group 2: Menomune® A/C/Y/W 135 Vaccine	32

Erythema

Group	Value	95% CI
Group 1: MenACYW Conjugate Vaccine	23
Group 2: Menomune® A/C/Y/W 135 Vaccine	5

Swelling

Group	Value	95% CI
Group 1: MenACYW Conjugate Vaccine	15
Group 2: Menomune® A/C/Y/W 135 Vaccine	2

Fever

Group	Value	95% CI
Group 1: MenACYW Conjugate Vaccine	3
Group 2: Menomune® A/C/Y/W 135 Vaccine	1

Headache

Group	Value	95% CI
Group 1: MenACYW Conjugate Vaccine	47
Group 2: Menomune® A/C/Y/W 135 Vaccine	28

Malaise

Group	Value	95% CI
Group 1: MenACYW Conjugate Vaccine	44
Group 2: Menomune® A/C/Y/W 135 Vaccine	15

Myalgia

Group	Value	95% CI
Group 1: MenACYW Conjugate Vaccine	70
Group 2: Menomune® A/C/Y/W 135 Vaccine	26

Adverse events — posted to ClinicalTrials.gov

Time frame: Unsolicited AE data were collected from Day 0 up to Day 30 post-vaccination. The SRs were collected within 7 days post-vaccination. SAE information was collected throughout the trial (up to 30 days post-vaccination).. Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Group 1: MenACYW Conjugate Vaccine

Serious: 0/199 (0%)

Deaths: 0/199

Group 2: Menomune® A/C/Y/W 135 Vaccine

Serious: 0/100 (0%)

Deaths: 0/100

Other adverse events (6 terms — click to expand)

Reaction	System	Group 1: MenACYW Conjugate…	Group 2: Menomune® A/C/Y/W…
Myalgia	Musculoskeletal and connective tissue disorders	—	—
Injection Site Pain	General disorders	—	—
Headache	Nervous system disorders	—	—
Malaise	General disorders	—	—
Injection Site Erythema	General disorders	—	—
Injection Site Swelling	General disorders	—	—

Data from ClinicalTrials.gov NCT01732627 adverse events section.

Sponsor's own description

Primary objectives: * To describe the antibody responses to meningococcal serogroups A, C, Y, and W 135, measured by serum bactericidal assay using human complement (hSBA) and baby rabbit complement (rSBA), induced by a single dose of Meningococcal Polysaccharide (A, C, Y, and W 135) Tetanus Protein (MenACYW) Conjugate vaccine or Menomune® - A/C/Y/W 135. * To describe the safety profile of a single dose of MenACYW Conjugate vaccine or Menomune® - A/C/Y/W 135.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adults 56 years of age and older: a Phase II randomized study.
Kirstein J, Pina M, Pan J, Jordanov E, et al · · 2020 · cited 19× · PMID 32233961 · DOI 10.1080/21645515.2020.1733868
Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) administered as a booster to adults aged ≥59 years: A phase III randomized study.
Robertson CA, Jacqmein J, Selmani A, Galarza K, et al · · 2023 · cited 10× · PMID 36632042 · DOI 10.1080/21645515.2022.2160600
Immune persistence and booster response of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) 5 years after primary vaccination of adults at ≥56 years of age.
Robertson CA, Jacqmein J, Selmani A, Galarza K, et al · · 2024 · cited 3× · PMID 39555800 · DOI 10.1080/21645515.2024.2426868
A new quadrivalent meningococcal tetanus toxoid conjugate vaccine: Menquadfi® (MENACWY-TT).
Dinleyici EC, Ciftci E, Somer A, Yilmaz D, et al · · 2025 · cited 2× · PMID 40493501 · DOI 10.1080/21645515.2025.2516949
[<i>Health Technology Assessment</i> (HTA) of the introduction of additional cohorts for anti-meningococcal vaccination with quadrivalent conjugate vaccines in Italy].
Boccalini S, Panatto D, Mennini FS, Marcellusi A, et al · · 2021 · cited 2× · PMID 34622076 · DOI 10.15167/2421-4248/jpmh2021.62.1s1
Immunogenicity and Safety of Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) in Potential Hajj/Umrah Pilgrims Aged ≥ 56 Years: A Phase III, Open-Label Study.
Dbaibo GS, Balik I, Akdemir İ, Buzgan T, et al · · 2026 · PMID 41604139 · DOI 10.1007/s40121-025-01298-w
Modeling antibody persistence after MenACYW-TT vaccination and comparative analysis with other quadrivalent meningococcal vaccines.
Coudeville L, Bertrand-Gerentes I, Zocchetti C, Langevin E, et al · · 2025 · PMID 40640249 · DOI 10.1038/s41598-025-08112-0
1157. Immune Persistence and Booster Response of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) 5 Years After Primary Vaccination of Adults ≥59 Years of Age
· 2023

Verify or expand the search:

Other recruiting trials for Meningitis

Currently open trials in the same condition.

NCT07358910 — Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective · recruiting
NCT07332234 — Optic Nerve Ultrasound for Assessing Cerebral Inflammation and Intracranial Hypertension in Cerebral Pathologies · recruiting
NCT06995430 — A Phase 3 Study to Assess the Immune Response And Safety Of Rmenb+Omv Nz In Primed Healthy Participants (10 To 20 Years · Phase 3 · active not recruiting
NCT06592586 — A Follow-up Trial of GBS-NN/NN2 Vaccine in Healthy Pregnant Women · Phase 2, PHASE3 · active not recruiting
NCT06584864 — Bedside Ultrasound on the Effectiveness of Lumbar Puncture in Children. · NA · recruiting

Other Sanofi Pasteur, a Sanofi Company trials

Trials by the same sponsor.

NCT07536048 — A Longitudinal Study of Epstein-Barr Virus (EBV) Reactivation in Adults Aged 18 to 29 Years · not yet recruiting
NCT07222059 — Phase 3 Single Arm, Open Study on vYF in Adults · Phase 3 · completed
NCT07013747 — Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Participants With Mild Acne · Phase 1, PHASE2 · recruiting
NCT06838000 — Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) i · Phase 3 · active not recruiting
NCT06793826 — Post-marketing Surveillance Study for the Safety of a DTaP-IPV- HB-PRP~T Vaccine in Republic of Korea · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01732627 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sanofi Pasteur, a Sanofi Company
Last refreshed: 4 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01732627.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing

NCT01732627

Quick facts

Drugs / interventions tested

Conditions studied

Sponsor

Who can join

Results — posted to ClinicalTrials.gov

Adverse events — posted to ClinicalTrials.gov

Sponsor's own description

Publications & conference data

Related trials

Other recruiting trials for Meningitis

Other Sanofi Pasteur, a Sanofi Company trials

Verify against primary sources